269 Spam-Free Article(s) Found
Article Searches
Ligand Pharmaceuticals (LGND) Presents At Berenberg Conference USA - Slideshow https://seekingalpha.com/article/4177209-ligand-pharmaceuticals-lgnd-presents-berenberg-conference-usa-slideshow?source=feed_sector_healthcare May 25, 2018 - The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event.
AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint http://www.zacks.com/stock/news/305024/abbvies-imbruvicas-phase-iii-study-meets-primary-endpoint?cid=CS-ZC-FT-305024 May 25, 2018 - AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Agios (AGIO) Progressing Well on Pipeline Amid Competition http://www.zacks.com/stock/news/304941/agios-agio-progressing-well-on-pipeline-amid-competition?cid=CS-ZC-FT-304941 May 24, 2018 - Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.
SWTUY or LGND: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/304912/swtuy-or-lgnd-which-is-the-better-value-stock-right-now?cid=CS-ZC--304912 May 24, 2018 - SWTUY vs. LGND: Which Stock Is the Better Value Option?
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y http://www.zacks.com/stock/news/304716/dr-reddys-rdy-q4-earnings-fall-revenues-decline-y-y?cid=CS-ZC-FT-304716 May 23, 2018 - Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
Allergan Stock Down Since Q1 Earnings Report: Here's Why http://www.zacks.com/stock/news/304670/allergan-stock-down-since-q1-earnings-report-heres-why?cid=CS-ZC-FT-304670 May 23, 2018 - Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.
Entera Bio Re-Enters IPO Process https://seekingalpha.com/article/4176274-entera-bio-re-enters-ipo-process?source=feed_tag_ipo_analysis May 22, 2018 - Entera Bio has filed an amended registration statement reviving its IPO efforts.The firm is advancing a pipeline of hypoparathyroidism and osteoporosis treatment candidates.ENTX has found existing inv
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100 http://www.zacks.com/stock/news/304524/inovio-initiates-phase-ii-study-on-pipeline-drug-vgx-3100?cid=CS-ZC-FT-304524 May 22, 2018 - Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/304315/ligand-pharmaceuticals-lgnd-hits-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-304315 May 21, 2018 - Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia http://www.zacks.com/stock/news/304359/astrazenecas-lokelma-gains-fda-nod-to-treat-hyperkalemia?cid=CS-ZC-FT-304359 May 21, 2018 - AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

Pages: 123456...27

Page 1>
DeepLinks for Ligand Pharmaceuticals Incorporated
LGND - Google Finance https://www.google.com/finance?q=LGND Industry related info and international coverage Summary News
LGND - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=LGND Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options